Figure 1.

Size of SPMS subgroups relative to total study population in clinical trials for DMTs approved for active SPMS or RMS by year of RCT publication; y-axis denotes the size of the entire study population, x-axis denotes the year of RCT publication; bullet size denotes the relative size of the SPMS subgroup; n = total number of SPMS patients (percentage of SPMS patients in the total study population); yellow bullets denote SPMS label; blue bullets denote RMS label.

^aCladribine: 374 patients (28.2%) had a baseline EDSS of 4 or higher, indicating that a proportion of patients may have transitioned to SPMS.